Idera, Biocryst to merge, rebrand and focus in rare disease programs
A few months after Idera Pharmaceuticals $IDRA stirred up some positive buzz at ESMO with early stage data on its TLR9 program, the biotech announced plans today to merge with Research Triangle Park, NC-based Biocryst $BCRX.
While Idera has several cancer drug programs in play, the two companies are spotlighting the rare disease therapies now in development, with 4 late-stage and mid-stage efforts underway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
